INFLUENCE OF AZITHROMYCIN AND OTHER MACROLIDES ON THE INTRACELLULAR KILLING OF STAPHYLOCOCCUS-AUREUS BY HUMAN POLYMORPHONUCLEAR LEUKOCYTES OF HEALTHY DONORS AND A PATIENT WITH CHEDIAK-HIGASHI-SYNDROME

被引:7
作者
PAULSEN, P
SIMON, C
PETERS, O
HEDDERICH, J
HEIM, P
机构
[1] UNIV KIEL,DEPT PAEDIAT,W-2300 KIEL 1,GERMANY
[2] UNIV KIEL,DEPT MED STAT,W-2300 KIEL 1,GERMANY
关键词
AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; ROXITHROMYCIN; MACROLIDE; POLYMORPHONUCLEAR; LEUKOCYTE; CHEDIAK-HIGASHI SYNDROME;
D O I
10.1159/000238961
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A mixture of human blood phagocytes from healthy donors and opsonized staphylococci was incubated in vitro for 30 min. After that time all the bacteria were phagocytosed. The test tubes were further incubated for 2, 4 and 24 h with or without addition of a macrolide (erythromycin, azithromycin, clarithromycin, roxithromycin) and the effect of these drugs on the survival of intracellular staphylococci (Staphylococcus aureus ATCC 25923) was measured. The minimal effective concentration of the antibiotic which killed 80-90% of the bacteria after a 4-hour incubation was 0.1 mg/l for erythromycin, azithromycin and clarithromycin and 1.2 mg/l for roxithromycin. The percentage of surviving bacteria after 2 and 4 h incubation was not significantly different between these macrolides at the minimal effective concentration. Increasing the concentration of each antibiotic above the minimal effective concentration did not alter the killing rate of intracellular staphylococci. The bacterial activity of polymorphonuclear leucocytes (PMNL) from a patient with Chediak-Higashi syndrome was less in comparison to PMNL from healthy donors, but was improved in vitro by the addition of erythromycin or azithromycin.
引用
收藏
页码:185 / 190
页数:6
相关论文
共 18 条
[1]   AN INVITRO EVALUATION OF THE CELLULAR UPTAKE AND INTRAPHAGOCYTIC BIOACTIVITY OF CLARITHROMYCIN (A-56268, TE-031), A NEW MACROLIDE ANTIMICROBIAL AGENT [J].
ANDERSON, R ;
JOONE, G ;
VANRENSBURG, CEJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 (06) :923-933
[2]   AN INVITRO COMPARISON OF THE INTRAPHAGOCYTIC BIOACTIVITY OF ERYTHROMYCIN AND ROXITHROMYCIN [J].
ANDERSON, R ;
VANRENSBURG, CEJ ;
JOONE, G ;
LUKEY, PT .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 :57-68
[3]   CELLULAR UPTAKE AND SUBCELLULAR-DISTRIBUTION OF ROXITHROMYCIN AND ERYTHROMYCIN IN PHAGOCYTIC-CELLS [J].
CARLIER, MB ;
ZENEBERGH, A ;
TULKENS, PM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 :47-56
[4]  
CRAIG CP, 1966, J IMMUNOL, V97, P287
[5]  
DIXON WJ, 1988, BMDP BIOMEDICAL COMP, V1
[6]  
FIETTA A, 1986, MACROLIDES REV OUTLO, P114
[7]   INVITRO AND INVIVO UPTAKE OF AZITHROMYCIN (CP-62,993) BY PHAGOCYTIC-CELLS - POSSIBLE MECHANISM OF DELIVERY AND RELEASE AT SITES OF INFECTION [J].
GLADUE, RP ;
BRIGHT, GM ;
ISAACSON, RE ;
NEWBORG, MF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) :277-282
[8]   ENTRY OF ROXITHROMYCIN (RU-965), IMIPENEM, CEFOTAXIME, TRIMETHOPRIM, AND METRONIDAZOLE INTO HUMAN POLYMORPHONUCLEAR LEUKOCYTES [J].
HAND, WL ;
KINGTHOMPSON, N ;
HOLMAN, JW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1553-1557
[9]   PENETRATION OF MACROLIDES INTO HUMAN POLYMORPHONUCLEAR LEUKOCYTES [J].
ISHIGURO, M ;
KOGA, H ;
KOHNO, S ;
HAYASHI, T ;
YAMAGUCHI, K ;
HIROTA, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (05) :719-729
[10]   SYNERGY BETWEEN RU-28965 (ROXITHROMYCIN) AND HUMAN-NEUTROPHILS FOR BACTERICIDAL ACTIVITY INVITRO [J].
LABRO, MT ;
AMIT, N ;
BABINCHEVAYE, C ;
HAKIM, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (01) :137-142